SARS-CoV-2-reactive T cells in patients and healthy donors [0.03%]
新型冠状病毒(SARS-CoV-2)特异T细胞在患者及健康供者中的分布特点
Luisanna Pia
Luisanna Pia
Conor Gruber
Conor Gruber
Alexandra Flemming
Alexandra Flemming
Giulia Petroni,Silvia C Formenti,Selina Chen-Kiang et al.
Giulia Petroni et al.
Cell cycle proteins that are often dysregulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracted considerable interest as potential targets for cancer therapy. In this context, multiple inhibitors of CDK...
Peter J Hotez,David B Corry,Maria Elena Bottazzi
Peter J Hotez
Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19...
Matthew Zirui Tay,Chek Meng Poh,Laurent Rénia et al.
Matthew Zirui Tay et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiol...
Miriam Saffern
Miriam Saffern
Verena van der Heide
Verena van der Heide
Samarth Hegde
Samarth Hegde
Antonio M Risitano,Dimitrios C Mastellos,Markus Huber-Lang et al.
Antonio M Risitano et al.
There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.